Table 3. Prediction model^a for the detection of ≥1 adenoma per patient based on multivariable logistic regression within the derivation cohort.

Factors	Uncorrected multivariable OR [95%-CI]	Correctedb β coefficients	Correctedb multivariable OR [95%-CI]
Intercept	-	-3.134	-
Age (per year increase)	1.02 [1.02–1.03]	0.023	1.02 [1.02–1.03]
Female	1.00 (ref)	0 (ref)	1.00 (ref)
Male	1.76 [1.62–1.92]	0.549	1.73 [1.60–1.88]
BMI (per kg/m2 increase)	1.02 [1.01–1.03]	0.017	1.02 [1.01–1.03]
ASA I	1.00 (ref)	0 (ref)	1.00 (ref)
ASA II	1.30 [1.18–1.44]	0.256	1.29 [1.17–1.43]
ASA III or IV	1.59 [1.34–1.90]	0.451	1.57 [1.32–1.86]
Ethnicity
Not Hispanic or Latino	1.00 (ref)	0 (ref)	1.00 (ref)
Hispanic or Latino	1.13 [1.00–1.28]	0.122	1.13 [1.00–1.27]
Unknown or patient declined to provide	1.16 [1.05–1.29]	0.148	1.16 [1.05–1.28]
Indication for colonoscopyc
Screening	1.00 (ref)	0 (ref)	1.00 (ref)
Surveillance	1.41 [1.28–1.55]	0.332	1.39 [1.27–1.53]

ASA, American Society of Anesthesiology physical status class; BMI, body mass index; CI, confidence interval; OR, odds ratio; ref, reference category.

^aThe presented odds ratios are adjusted for EQUIP intervention (colonoscopy performed after versus no intervention received) which had an uncorrected OR of 1.24 [95%-CI: 1.13–1.36] in the final model.

^bCorrected after internal validation using bootstrap resampling with a shrinkage factor of 0.969. The intercept is additionally corrected by subtraction of the intercept correction of -0.017.

^cThe indication is considered surveillance for patients with a personal history of colorectal adenomas or surveillance marked as indication on the GastroIntestinal Quality Improvement Consortium (GIQuIC) form.